Download PDF
Nephrologie aktuell 2024; 28(05): 214-221
DOI: 10.1055/a-2268-3875
Schwerpunkt
Dialyse

Kontinuierliche Nierenersatztherapie

Troubleshooting
Nicole Bethke
1   Klinik für Nephrologie, Vivantes Klinikum Friedrichshain, Berlin
,
Dmytro Khadzhynov
2   KfH-Nierenzentrum Berlin Mitte, Berlin
3   Innere Medizin, St. Hedwig-Krankenhaus, Berlin
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Zusammenfassend stellt die kontinuierliche Nierenersatztherapie (CKRT: „continuous kidney replacement therapy“) eine sichere Option der Nierenersatztherapie (KRT) dar. Durch die lokale Wirksamkeit der zitratbasierten Antikoagulation wird eine systemische Antikoagulation vermieden und das Blutungsrisiko reduziert. Ebenso ermöglicht die Verwendung der regionalen Antikoagulation eine unkomplizierte Anpassung an spezifische klinische Gegebenheiten. Dennoch ist es wichtig, den Elektrolythaushalt während der CKRT sorgfältig zu überwachen, um potenzielle Überdosierungen und mögliche Komplikationen zu minimieren sowie die Effektivität des Verfahrens zu gewährleisten. In diesem Artikel geben wir einen Überblick über die am häufigsten auftretenden Komplikationen während der CKRT-Anwendung, wobei der Fokus auf der Optimierung und Fehlerbehebung von Antikoagulation und Elektrolytstörungen liegt – letztlich Faktoren, die die Sicherheit und Effektivität des Verfahrens maßgeblich definieren.



Publication History

Article published online:
25 June 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Kramer P, Wigger W, Rieger J. et al [Arteriovenous haemofiltration: a new and simple method for treatment of over-hydrated patients resistant to diuretics]. Klin Wochenschr 1977; 55: 1121-1122
    CrossrefPubMedGoogle Scholar
  • 2 Neyra JA, Yessayan L, Thompson Bastin ML. et al How to prescribe and troubleshoot continuous renal replacement therapy: a case-based review. Kidney360 2020; 02: 371-384
    CrossrefPubMedGoogle Scholar
  • 3 Bell M, SWING Granath F. et al Continuous renal replacement therapy is associated with less chronic renal failure than intermittent haemodialysis after acute renal failure. Intensive Care Med 2007; 33: 773-780
    CrossrefPubMedGoogle Scholar
  • 4 Wang AY, Bellomo R. Renal replacement therapy in the ICU: intermittent hemodialysis, sustained low-efficiency dialysis or continuous renal replacement therapy?. Curr Opin Crit Care 2018; 24: 437-442
    CrossrefPubMedGoogle Scholar
  • 5 Wald R, Shariff SZ, Adhikari NK. et al The association between renal replacement therapy modality and long-term outcomes among critically ill adults with acute kidney injury: a retrospective cohort study. Crit Care Med 2014; 42: 868-877
    CrossrefPubMedGoogle Scholar
  • 6 Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012; 02: 1-138
    CrossrefGoogle Scholar
  • 7 Neyra JA, Goldstein SL. Optimizing renal replacement therapy deliverables through multidisciplinary work in the intensive care unit. Clin Nephrol 2018; 90: 1-5
    CrossrefPubMedGoogle Scholar
  • 8 Rewa OG, Villeneuve PM, Lachance P. et al Quality indicators of continuous renal replacement therapy (CRRT) care in critically ill patients: a systematic review. Intensive Care Med 2017; 43: 750-763
    CrossrefPubMedGoogle Scholar
  • 9 Ronco C, Bellomo R. Acute renal failure in patients with kidney transplant: continuous versus intermittent renal replacement therapy. Ren Fail 1996; 18: 461-470
    CrossrefPubMedGoogle Scholar
  • 10 Ronco C, Ricci Z. Renal replacement therapies: physiological review. Intensive Care Med 2008; 34: 2139-2146
    CrossrefPubMedGoogle Scholar
  • 11 Joannidis M, Oudemans-van Straaten HM. Clinical review: Patency of the circuit in continuous renal replacement therapy. Crit Care 2007; 11: 218
    CrossrefPubMedGoogle Scholar
  • 12 Uchino S, Bellomo R, Morimatsu H. et al Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B. E. S. T. kidney) investigators. Intensive Care Med 2007; 33: 1563-1570
    PubMedGoogle Scholar
  • 13 Hetzel GR, Schmitz M, Wissing H. et al Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011; 26: 232-239
    CrossrefPubMedGoogle Scholar
  • 14 Bai M, Zhou M, He L. et al Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intensive Care Med 2015; 41: 2098-2110
    CrossrefPubMedGoogle Scholar
  • 15 Gattas DJ, Rajbhandari D, Bradford C. et al A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Crit Care Med 2015; 43: 1622-1629
    CrossrefPubMedGoogle Scholar
  • 16 Oudemans-van Straaten HM, Bosman RJ, Koopmans M. et al Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37: 545-552
    CrossrefPubMedGoogle Scholar
  • 17 Schilder L, Nurmohamed SA, Bosch FH. et al Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Crit Care 2014; 18: 472
    CrossrefPubMedGoogle Scholar
  • 18 Stucker F, Ponte B, Tataw J. et al Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Crit Care 2015; 19: 91
    CrossrefPubMedGoogle Scholar
  • 19 Zhang Z, Hongying N. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med 2012; 38: 20-28
    CrossrefPubMedGoogle Scholar
  • 20 Zarbock A, Kullmar M, Kindgen-Milles D. et al Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury: a randomized clinical trial. JAMA 2020; 324: 1629-1639
    CrossrefPubMedGoogle Scholar
  • 21 Jacobs R, Honore PM, Hendrickx I. et al Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy:. All Citrates Are Not Created Equal! Blood Purif 2016; 42: 219-220
    PubMedGoogle Scholar
  • 22 Meier-Kriesche HU, Gitomer J, Finkel K. et al Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med 2001; 29: 748-752
    CrossrefPubMedGoogle Scholar
  • 23 Schultheiß C, Saugel B, Phillip V. et al Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care 2012; 16: R162
    CrossrefPubMedGoogle Scholar
  • 24 Honore PM, Mugisha A, David C. et al In severe liver disease, citrate can be used safely: the question remains-by which mechanism. Crit Care 2020; 24: 63
    CrossrefPubMedGoogle Scholar
  • 25 Klingele M, Stadler T, Fliser D. et al Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction. Crit Care 2017; 21: 294
    CrossrefPubMedGoogle Scholar
  • 26 Slowinski T, Morgera S, Joannidis M. et al Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care 2015; 19: 349
    CrossrefPubMedGoogle Scholar
  • 27 Khadzhynov D, Dahlinger A, Schelter C. et al Hyperlactatemia, lactate kinetics and prediction of citrate accumulation in critically ill patients undergoing continuous renal replacement therapy with regional citrate anticoagulation. Crit Care Med 2017; 45: e941-e946
    CrossrefPubMedGoogle Scholar
  • 28 Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy 2012; 32: 546-558
    CrossrefPubMedGoogle Scholar
  • 29 Endres P, Rosovsky R, Zhao S. et al Filter clotting with continuous renal replacement therapy in COVID-19. J Thromb Thrombolysis 2021; 51: 966-970
    CrossrefPubMedGoogle Scholar
  • 30 Dingman JS, Smith ZR, Coba VE. et al Argatroban dosing requirements in extracorporeal life support and other critically ill populations. Thromb Res 2020; 189: 69-76
    CrossrefPubMedGoogle Scholar
  • 31 Keegan SP, Gallagher EM, Ernst NE. et al Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia. Ann Pharmacother 2009; 43: 19-27
    CrossrefPubMedGoogle Scholar
  • 32 Shankaranarayanan D, Muthukumar T, Barbar T. et al Anticoagulation strategies and filter life in COVID-19 patients receiving continuous renal replacement therapy: a single-center experience. Clin J Am Soc Nephrol 2020; 16: 124-12
    CrossrefPubMedGoogle Scholar
  • 33 Valle EO, Cabrera CPS, Albuquerque CCC. et al Continuous renal replacement therapy in COVID-19-associated AKI: adding heparin to citrate to extend filter life-a retrospective cohort study. Crit Care 2021; 25: 299
    CrossrefPubMedGoogle Scholar
  • 34 Nash DM, Przech S, Wald R. et al Systematic review and meta-analysis of renal replacement therapy modalities for acute kidney injury in the intensive care unit. J Crit Care 2017; 41: 138-144
    CrossrefPubMedGoogle Scholar
  • 35 Schneider AG, Journois D, Rimmele T. Complications of regional citrate anticoagulation: accumulation or overload?. Crit Care 2017; 21: 281
    CrossrefPubMedGoogle Scholar
  • 36 Morgera S, Schneider M, Slowinski T. et al A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med 2009; 37: 2018-2024
    CrossrefPubMedGoogle Scholar
  • 37 Davenport A, Tolwani A. Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. NDT Plus 2009; 02: 439-447
    Google Scholar
  • 38 Zheng Y, Zhuang F, Zhu Q. et al Albumin-corrected total/ionized calcium ratio is not superior to total/ionized calcium ratio as an indicator of citrate accumulation. Int J Artif Organs 2017; 40: 602-606
    CrossrefPubMedGoogle Scholar
  • 39 Tan JN, Haroon SWP, Mukhopadhyay A. et al Hyperlactatemia predicts citrate intolerance with regional citrate anticoagulation during continuous renal replacement therapy. J Intensive Care Med 2019; 34: 418-425
    CrossrefPubMedGoogle Scholar
  • 40 Zhang W, Bai M, Yu Y. et al Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit Care 2019; 23: 22
    CrossrefPubMedGoogle Scholar
  • 41 Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med 2000; 26: 1652-1657
    CrossrefPubMedGoogle Scholar
  • 42 Parienti JJ, Megarbane B, Fischer MO. et al Catheter dysfunction and dialysis performance according to vascular access among 736 critically ill adults requiring renal replacement therapy: a randomized controlled study. Crit Care Med 2010; 38: 1118-1125
    CrossrefPubMedGoogle Scholar
  • 43 Morgera S, Scholle C, Voss G. et al Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron Clin Pract 2004; 97: c131-c136
    CrossrefPubMedGoogle Scholar
  • 44 Morgera S, Haase M, Ruckert M. et al Regional citrate anticoagulation in continuous hemodialysis--acid-base and electrolyte balance at an increased dose of dialysis. Nephron Clin Pract 2005; 101: c211-c219
    CrossrefPubMedGoogle Scholar
  • 45 Adrogue HJ, Madias NE. Hypernatremia. N Engl J Med 2000; 342: 1493-1499
    CrossrefPubMedGoogle Scholar
  • 46 Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342: 1581-1589
    CrossrefPubMedGoogle Scholar
  • 47 Ostermann M, Dickie H, Tovey L. et al Management of sodium disorders during continuous haemofiltration. Crit Care 2010; 14: 418
    CrossrefPubMedGoogle Scholar
  • 48 Huang WY, Weng WC, Peng TI. et al Central pontine and extrapontine myelinolysis after rapid correction of hyponatremia by hemodialysis in a uremic patient. Ren Fail 2007; 29: 635-638
    CrossrefPubMedGoogle Scholar
  • 49 Peces R, Ablanedo P, Alvarez J. et al Central pontine and extrapontine myelinolysis following correction of severe hyponatremia. Nephron 1988; 49: 160-163
    CrossrefPubMedGoogle Scholar
  • 50 Yessayan L, Yee J, Frinak S. et al Treatment of severe hyponatremia in patients with kidney failure: role of continuous venovenous hemofiltration with low-sodium replacement fluid. Am J Kidney Dis 2014; 64: 305-310
    CrossrefPubMedGoogle Scholar
  • 51 Paquette F, Goupil R, Madore F. et al Continuous venovenous hemofiltration using customized replacement fluid for acute kidney injury with severe hypernatremia. Clin Kidney J 2016; 09: 540-542
    CrossrefPubMedGoogle Scholar
  • 52 Neyra JA, Ortiz-Soriano VM, Ali D. et al A multidisciplinary approach for the management of severe hyponatremia in patients requiring continuous renal replacement therapy. Kidney Int Rep 2019; 04: 59-66
    CrossrefPubMedGoogle Scholar
  • 53 Yessayan L, Yee J, Frinak S. et al Continuous renal replacement therapy for the management of acid-base and electrolyte imbalances in acute kidney injury. Adv Chronic Kidney Dis 2016; 23: 203-210
    CrossrefPubMedGoogle Scholar
  • 54 Geerse DA, Bindels AJ, Kuiper MA. et al Treatment of hypophosphatemia in the intensive care unit: a review. Crit Care 2010; 14: R147
    CrossrefPubMedGoogle Scholar
  • 55 Heung M, Mueller BA. Prevention of hypophosphatemia during continuous renal replacement therapy – An overlooked problem. Semin Dial 2018; 31: 213-218
    CrossrefPubMedGoogle Scholar
  • 56 Broman M, Carlsson O, Friberg H. et al Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy. Acta Anaesthesiol Scand 2011; 55: 39-45
    CrossrefPubMedGoogle Scholar
  • 57 Aubier M, Murciano D, Lecocguic Y. et al Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure. N Engl J Med 1985; 313: 420-424
    CrossrefPubMedGoogle Scholar
  • 58 Demirjian S, Teo BW, Guzman JA. et al Hypophosphatemia during continuous hemodialysis is associated with prolonged respiratory failure in patients with acute kidney injury. Nephrol Dial Transplant 2011; 26: 3508-3514
    CrossrefPubMedGoogle Scholar
  • 59 Yang Y, Zhang P, Cui Y. et al Hypophosphatemia during continuous veno-venous hemofiltration is associated with mortality in critically ill patients with acute kidney injury. Crit Care 2013; 17: R205
    CrossrefPubMedGoogle Scholar
  • 60 Thompson Bastin ML, Stromberg AJ, Nerusu SN. et al Association of phosphate-containing versus phosphate-free solutions on ventilator days in patients requiring continuous kidney replacement therapy. Clin J Am Soc Nephrol 2022; 17: 634-642
    CrossrefPubMedGoogle Scholar